Different molecular signaling sustaining adiponectin action in breast cancer

Current Opinion in Pharmacology

Volumn 31, Issue , 2016, Pages 1-7

  Panno, Maria Luisa ^a   Naimo, Giuseppina Daniela ^a   Spina, Elena ^a   Andò, Sebastiano ^a   Mauro, Loredana ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR AGONIST; ADP 355; ARCTIIN; CYTOKINE RECEPTOR AGONIST; ESTROGEN RECEPTOR ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER KINASE B1; MATAIRESINOL; METFORMIN; NATURAL PRODUCT; PARTHENOLIDE; PROTEIN KINASE; ROSIGLITAZONE; TAXIFOLIOL; TROGLITAZONE; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CALORIC RESTRICTION; CANCER GROWTH; DIETARY FIBER; DRUG TARGETING; FAT INTAKE; HUMAN; HYPOADIPONECTINEMIA; LIFESTYLE MODIFICATION; OBESITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; WNT SIGNALING PATHWAY; ADIPOSE TISSUE; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; METABOLISM; PHYSIOLOGY;

ADIPONECTIN; ADIPOSE TISSUE; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; OBESITY; SIGNAL TRANSDUCTION;

EID: 84982227929     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.08.001     Document Type: Review

References (57)

1. 1• Nagaraju, G.P., Rajitha, B., Aliya, S., Kotipatruni, R.P., Madanraj, A.S., Hammond, A., Park, D., Chigurupati, S., Alam, A., Pattnaik, S., The role of adiponectin in obesity-associated female-specific carcinogenesis. Cytokine Growth Factor Rev, 2016 pii: S1359-6101(16)30005-3 This review highlights the molecular mechanisms of adiponectin action in breast cancer etiology.
2. 2 Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001), 941–946.
3. 3 Berg, A.H., Combs, T.P., Du, X., Brownlee, M., Scherer, P.E., The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001), 947–953.
4. 4•• Deng, T., Lyon, C.J., Bergin, S., Caligiuri, M.A., Hsueh, W.A., Obesity, Inflammation and cancer. Annu Rev Pathol 11 (2016), 421–449 This review focuses on the mechanisms linking obesity to cancer, describing how the adipose-derived factors are able to influence tumor growth, metastasis, and progression.
5. 5 Macciò, A., Madeddu, C., Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. Sci World J 11 (2011), 2020–2036.
6. 6 Mauro, L., Salerno, M., Panno, M.L., Bellizzi, D., Sisci, D., Miglietta, A., Surmacz, E., Andò, S., Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells. Biochem Biophys Res Commun 288 (2001), 685–689.
7. 7 Dalamaga, M., Diakopoulos, K.N., Mantzoros, C.S., The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33 (2012), 547–594.
8. 8 Chandran, M., Phillips, S.A., Ciaraldi, T., Henry, R.R., Adiponectin: more than just another fat cell hormone?. Diabetes Care 26 (2003), 2442–2450.
9. 9 Mantzoros, C., Petridou, E., Dessypris, N., Chavelas, C., Dalamaga, M., Alexe, D.M., Papadiamantis, Y., Markopoulos, C., Spanos, E., Chrousos, G., Trichopoulos, D., Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89 (2004), 1102–1107.
10. 10 Petridou, E., Mantzoros, C., Dessypris, N., Koukoulomatis, P., Addy, C., Voulgaris, Z., Chrousos, G., Trichopoulos, D., Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 88 (2003), 993–997.
11. 11 Goktas, S., Yilmaz, M.I., Caglar, K., Sonmez, A., Kilic, S., Bedir, S., Prostate cancer and adiponectin. Urology 65 (2005), 1168–1172.
12. 12 Ishikawa, M., Kitayama, J., Kazama, S., Hiramatsu, T., Hatano, K., Nagawa, H., Plasma adiponectin and gastric cancer. Clin Cancer Res 11 (2005), 466–472.
13. 13 Arano, T., Nakagawa, H., Tateishi, R., Ikeda, H., Uchino, K., Enooku, K., Goto, E., Masuzaki, R., Asaoka, Y., Kondo, Y., et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer 129 (2011), 2226–2235.
14. 14 Stolzenberg-Solomon, R.Z., Weinstein, S., Pollak, M., Tao, Y., Taylor, P.R., Virtamo, J., Albanes, D., Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 168 (2008), 1047–1055.
15. 15 Petridou, E.T., Sergentanis, T.N., Dessypris, N., Vlachantoni, I.T., Tseleni-Balafouta, S., Pourtsidis, A., Moschovi, M., Polychronopoulou, S., Athanasiadou-Piperopoulou, F., Kalmanti, M., Mantzoros, C.S., Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study. J Clin Oncol 27 (2009), 5049–5055.
16. 16 Petridou, E., Mantzoros, C.S., Dessypris, N., Dikalioti, S.K., Trichopoulos, D., Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 94 (2006), 156–160.
17. 17 Hu, E., Liang, P., Spiegelman, B.M., AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271 (1996), 10697–10703.
18. 18 Takahashi, M., Arita, Y., Yamagata, K., Matsukawa, Y., Okutomi, K., Horie, M., Shimomura, I., Hotta, K., Kuriyama, H., Kihara, S., et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24 (2000), 861–868.
19. 19 Menzaghi, C., Ercolino, T., Di Paola, R., Berg, A.H., Warram, J.H., Scherer, P.E., Trischitta, V., Doria, A., A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51 (2002), 2306–2312.
20. 20 Kaklamani, V.G., Sadim, M., Hsi, A., Offit, K., Oddoux, C., Ostrer, H., Ahsan, H., Pasche, B., Mantzoros, C., Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 68 (2008), 3178–3184.
21. 21 Lopez-Jaramillo, P., The role of adiponectin in cardiometabolic diseases: effects of nutritional interventions. J Nutr 146 (2016), 422S–426S.
22. 22• Guo, M.M., Duan, X.N., Cui, S.D., Tian, F.G., Cao, X.C., Geng, C.Z., Fan, Z.M., Wang, X., Wang, S., Jiang, H.C., Circulating High-Molecular-Weight (HMW) adiponectin level is related with breast cancer risk better than total adiponectin: a Case-Control study. PLoS One, 10, 2015, e0129246 This case–control study demonstrates that different forms of circulating adiponectin levels may play different roles in breast cancer risk.
23. 23 Brochu-Gaudreau, K., Rehfeldt, C., Blouin, R., Bordignon, V., Murphy, B.D., Palin, M.F., Adiponectin action from head to toe. Endocrine 37 (2010), 11–32.
24. 24 Tanabe, H., Fujii, Y., Okada-Iwabu, M., Iwabu, M., Nakamura, Y., Hosaka, T., Motoyama, K., Ikeda, M., Wakiyama, M., Terada, T., Crystal structures of the human adiponectin receptors. Nature 520 (2015), 312–316.
25. 25 Kadowaki, T., Yamauchi, T., Adiponectin and adiponectin receptors. Endocr Rev 26 (2005), 439–451.
26. 26 Hug, C., Wang, J., Ahmad, N.S., Bogan, J.S., Tsao, T.S., Lodish, H.F., T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci 101 (2004), 10308–10313.
27. 27 Denzel, M.S., Scimia, M.C., Zumstein, P.M., Walsh, K., Ruiz-Lozano, P., Ranscht, B., T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120 (2010), 4342–4352.
28. 28 Shackelford, D.B., Shaw, R.J., The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9 (2009), 563–575.
29. 29•• Katira, A., Tan, P.H., Evolving role of adiponectin in cancer-controversies and update. Cancer Biol Med 13 (2016), 101–119 Relevant review on the role of adiponectin in cancer with an interesting summary on therapeutic interventions.
30. 30 Shen, Z., Wen, X.F., Lan, F., Shen, Z.Z., Shao, Z.M., The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res 8 (2002), 2085–2090.
31. 31 Alessi, D.R., Sakamoto, K., Bayascas, J.R., LKB1-dependent signaling pathways. Annu Rev Biochem 75 (2006), 137–163.
32. 32 Baas, A.F., Boudeau, J., Sapkota, G.P., Smit, L., Medema, R., Morrice, N.A., Alessi, D.R., Clevers, H.C., Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J 22 (2003), 3062–3072.
33. 33 Boudeau, J., Baas, A.F., Deak, M., Morrice, N.A., Kieloch, A., Schutkowski, M., Prescott, A.R., Clevers, H.C., Alessi, D.R., MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 22 (2003), 5102–5114.
34. 34 Mauro, L., Naimo, G.D., Ricchio, E., Panno, M.L., Andò, S., Cross-talk between adiponectin and IGF-IR in breast cancer. Front Oncol, 5, 2015, 157.
35. 35 Zhuang, Z.G., Di, G.H., Shen, Z.Z., Ding, J., Shao, Z.M., Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res 4 (2006), 843–849.
36. 36 Luo, Z., Saha, A.K., Xiang, X., Ruderman, N.B., AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26 (2005), 69–76.
37. 37 Shaw, R.J., LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 196 (2009), 65–80.
38. 38 Obeid, S., Hebbard, L., Role of adiponectin and its receptors in cancer. Cancer Biol Med 9 (2012), 213–220.
39. 39 Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., Cantley, L.C., Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10 (2002), 151–162.
40. 40 Marygold, S.J., Leevers, S.J., Growth signaling: TSC takes its place. Curr Biol 12 (2002), R785–R787.
41. 41 Fresno Vara, J.A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., González-Barón, M., PI3K/Akt signaling pathway and cancer. Cancer Treat Rev 30 (2004), 193–204.
42. 42 Dieudonne, M.N., Bussiere, M., Dos Santos, E., Leneveu, M.C., Giudicelli, Y., Pecquery, R., Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345 (2006), 271–279.
43. 43 Wang, Y., Lam, J.B., Lam, K.S., Liu, J., Lam, M.C., Hoo, R.L., Wu, D., Cooper, G.J., Xu, A., Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66 (2006), 11462–11470.
44. 44 Kang, J.H., Lee, Y.Y., Yu, B.Y., Yang, B.S., Cho, K.H., Yoon, D.K., Roh, Y.K., Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28 (2005), 1263–1269.
45. 45 Dos Santos, E., Benaitreau, D., Dieudonne, M.N., Leneveu, M.C., Serazin, V., Giudicelli, Y., Pecquery, R., Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 20 (2008), 971–977.
46. 46 Grossmann, M.E., Nkhata, K.J., Mizuno, N.K., Ray, A., Cleary, M.P., Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98 (2008), 370–379.
47. 47 Pfeiler, G.H., Buechler, C., Neumeier, M., Schäffler, A., Schmitz, G., Ortmann, O., Treeck, O., Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep 19 (2008), 787–793.
48. 48 Landskroner-Eiger, S., Qian, B., Muise, E.S., Nawrocki, A.R., Berger, J.P., Fine, E.J., Koba, W., Deng, Y., Pollard, J.W., Scherer, P.E., Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 15 (2009), 3265–3276.
49. 49• Mauro, L., Pellegrino, M., De Amicis, F., Ricchio, E., Giordano, F., Rizza, P., Catalano, S., Bonofiglio, D., Sisci, D., Panno, M.L., et al. Evidences that estrogen receptor α interferes with adiponectin effects on breast cancer cell growth. Cell Cycle 13 (2014), 553–564 This study demonstrates how adiponectin, through the activation of ER-α at nongenomic and genomic levels, increase breast cancer cell growth.
50. 50• Mauro, L., Pellegrino, M., Giordano, F., Ricchio, E., Rizza, P., De Amicis, F., Catalano, S., Bonofiglio, D., Panno, M.L., Andò, S., Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells. FASEB J 29 (2015), 2150–2160 This study shows that adiponectin differently affects breast cancer growth accordingly to ER-α expression, through the opposite modulation of cyclin D1.
51. 51 Otvos, L. Jr., Haspinger, E., La Russa, F., Maspero, F., Graziano, P., Kovalszky, I., Lovas, S., Nama, K., Hoffmann, R., Knappe, D., et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol, 11, 2011, 90.
52. 52 Surmacz, E., Leptin and adiponectin: emerging therapeutic targets in breast cancer. J Mammary Gland Biol Neoplasia 18 (2013), 321–332.
53. 53• Surmacz, E., Otvos, L., Molecular targeting of obesity pathways in cancer. Horm Mol Biol Clin Investig 22 (2015), 53–62 Original review dealing with the adiponectin receptor agonists designed for the treatment of obesity-associated breast cancer.
54. 54•• Otvos, L. Jr., Kovalszky, I., Olah, J., Coroniti, R., Knappe, D., Nollmann, F.I., Hoffmann, R., Wade, J.D., Lovas, S., Surmacz, E., Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling. Biopolymers 104 (2015), 156–166 This study demonstrates that structural modification of ADP355, ligand of the adiponectin receptor, increases the agonistic activity up to 5-10 fold and antagonizes tumor development at multiple stages.
55. 55 Sun, Y., Zang, Z., Zhong, L., Wu, M., Su, Q., Gao, X., Zan, W., Lin, D., Zhao, Y., Zhang, Z., Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One, 8, 2013, e63354.
56. 56 Khan, S., Shukla, S., Sinha, S., Meeran, S.M., Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev 24 (2013), 503–513.
57. 57 Wei, S., Yang, J., Lee, S.L., Kulp, S.K., Chen, C.S., PPARgamma independent antitumor effects of thiazolidinediones. Cancer Lett 276 (2009), 119–124.